Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...
Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...
William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...
Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...
3h
Investor's Business Daily on MSNIncyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.
Research analysts at William Blair upped their FY2025 EPS estimates for shares of ABM Industries in a report issued on ...
JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...
The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.
Palantir (NASDAQ:PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price ...
Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...
The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results